CN114272273A - NMN-containing antioxidant composition and preparation method thereof - Google Patents
NMN-containing antioxidant composition and preparation method thereof Download PDFInfo
- Publication number
- CN114272273A CN114272273A CN202011037885.4A CN202011037885A CN114272273A CN 114272273 A CN114272273 A CN 114272273A CN 202011037885 A CN202011037885 A CN 202011037885A CN 114272273 A CN114272273 A CN 114272273A
- Authority
- CN
- China
- Prior art keywords
- mass
- parts
- antioxidant composition
- nmn
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses an NMN-containing antioxidant composition and a preparation method thereof, wherein the NMN-containing antioxidant composition is prepared from the following raw materials in parts by mass: 10-13 parts of nicotinamide mononucleotide, 100.02-0.06 parts of coenzyme Q, 0.2-0.5 part of plasmalogen, 0.8-2.0 parts of nucleic acid, 0.05-1 part of amino acid, 0.2-0.5 part of vitamin and 0.005-0.08 part of trace element. The antioxidant composition provided by the invention adopts specific components and specific proportions, is reasonable in formula and proper in compatibility, has the advantages of good antioxidant and anti-aging effects, no harm to human bodies and stable product quality, and is convenient to use, good in absorption effect, free of adverse effects and toxic and side effects.
Description
Technical Field
The invention relates to the technical field of health products, in particular to an NMN-containing antioxidant composition and a preparation method thereof.
Background
Along with the continuous improvement of living standard of people, the attention of people on health and longevity is increasing day by day, and simultaneously, various anti-aging drugs are also like bamboo shoots in spring after rain to continuously flood the market, but the effects are good and different. In addition, the aging problem of the current society is serious, so that the deep research on the anti-aging compound medicine with remarkable effect is certainly beneficial to realizing the aim of healthy aging.
NAD + (nicotinamide adenine dinucleotide, also called coenzyme I) is an important coenzyme for the tricarboxylic acid cycle, promotes the metabolism of sugar, fat and amino acid, participates in the synthesis of energy, and is an important active substance participating in thousands of important physiological reactions such as cell metabolism, redox, protein transcription and the like. However, with age, NAD + levels are continually reduced and cellular metabolic capacity is affected. In humans NAD + is synthesized by Nicotinamide Mononucleotide (NMN), a precursor for the synthesis of NAD +. In 2013, professor David Sinclair issued text on cell: after one week of NAD elevation, 22-month old mice (equivalent to 60 years old in humans) and two former mice were fed with NMN, which were similar to 6-month old mice (equivalent to 20 years old in humans) in key indicators of mitochondrial homeostasis, muscle health, etc., and the lifespan of the mice was extended by 20%. Therefore, anti-aging products containing NMN are produced.
Most of NMN anti-aging products on the market at present are the combination of NMN and some Chinese herbal medicine components, and have the effect of enhancing the functions of human bodies to a certain extent, but the using effect is not ideal, and the anti-aging effect needs to be enhanced; some anti-aging products use industrial ingredients with strong oxidation resistance to achieve good anti-aging effect, take effect quickly in a short time, but are extremely harmful to human bodies after being used for a long time; some anti-aging products are poor in product stability although vitamin antioxidants are added.
Therefore, there is a need to develop an anti-oxidation and anti-aging composition for solving the technical defects that the anti-aging product in the prior art cannot achieve good anti-oxidation and anti-aging effects, is harmless to human body and has stable product quality.
Disclosure of Invention
The invention aims to overcome the defects that the anti-aging product in the prior art is difficult to realize good anti-oxidation and anti-aging effects, is harmless to human bodies and has stable product quality, and provides an anti-oxidation composition containing NMN and a preparation method thereof. The antioxidant composition provided by the invention has the advantages of good antioxidant and anti-aging effects, no harm to human bodies and stable product quality by adopting specific components and specific proportion and reasonable compatibility, is convenient to use, has a good absorption effect, and has no adverse or toxic side effects.
The invention solves the technical problems by the following scheme:
an antioxidant composition containing NMN is prepared from the following raw materials in parts by mass: 10-13 parts of nicotinamide mononucleotide, 100.02-0.06 parts of coenzyme Q, 0.2-0.5 part of plasmalogen, 0.8-2.0 parts of nucleic acid, 0.05-1 part of amino acid, 0.2-0.5 part of vitamin and 0.005-0.08 part of trace element in terms of effective components.
Preferably, the mass portion of nicotinamide mononucleotide is 10-12.8 parts, such as 10.64 parts, 12 parts or 12.8 parts, based on the active ingredient.
Preferably, the mass portion of the coenzyme Q10 is 0.028-0.06, such as 0.06, 0.048 or 0.026, calculated by the effective component.
Preferably, the mass portion of the plasmalogen is 0.24 to 0.45 parts, for example, 0.45 part, 0.24 part or 0.26 part, based on the active ingredient.
Preferably, the nucleic acid is present in an amount of 0.92 to 1.92 parts by mass, for example 0.92 parts or 1.92 parts, based on the active ingredient.
Preferably, the amino acid is 0.08 to 0.48 part by mass, for example, 0.08 part, 0.14 part or 0.48 part, based on the active ingredient.
Preferably, the vitamin is 0.25 to 0.3 part by mass, such as 0.26 part, 0.28 part or 0.3 part, based on the active ingredient.
Preferably, the mass part of the trace elements is 0.005-0.06 parts, such as 0.00642 parts or 0.0525 parts of the effective components.
Preferably, the antioxidant composition is prepared from the following raw materials in parts by mass: 10-12.8 parts of nicotinamide mononucleotide, 100.028-0.06 part of coenzyme Q, 0.24-0.45 part of plasmalogen, 0.92-1.92 parts of nucleic acid, 0.08-0.48 part of amino acid, 0.25-0.3 part of vitamin and 0.005-0.06 part of trace element in terms of effective components.
Preferably, the antioxidant composition is prepared from the following raw materials in parts by mass: 10-12.8 parts of nicotinamide mononucleotide, 100.028-0.06 part of coenzyme Q, 0.24-0.45 part of plasmalogen, 0.92-1.92 parts of nucleic acid, 0.08-0.48 part of amino acid, 0.25-0.3 part of vitamin and 0.005-0.06 part of trace element in terms of effective components.
In the invention, the source of the plasmalogen can be chicken breast plasmalogen powder.
Preferably, the nucleic acid comprises: RNA and/or DNA; wherein the source of the DNA can be salmon roe extract, and the source of the RNA can be beer yeast extract.
Preferably, the amino acids include: l-tryptophan and/or L-tyrosine.
Preferably, the vitamins include: a mixture of one or more of riboflavin (VB2), niacin (VB3), pyridoxine hydrochloride (VB6), vitamin E, and vitamin C;
preferably, the trace elements include: a mixture of one or more of zinc, manganese and selenium; wherein, the zinc source can be zinc-containing yeast, and the zinc content in the zinc-containing yeast is preferably 10% by mass; the manganese source can be manganese-containing yeast, and the manganese content in the manganese-containing yeast is preferably 5% by mass; the selenium source can be selenium-containing yeast, and the content of selenium in the selenium-containing yeast is preferably 0.2% by mass.
In a preferred embodiment of the invention, the antioxidant composition is prepared from the following raw materials in parts by mass: the traditional Chinese medicine composition comprises, by active ingredient, 10.64 parts of NMN, 100.06 parts of coenzyme Q, 0.45 part of plasmalogen, 0.96 part of DNA, 0.96 part of RNA, 0.28 part of L-tryptophan, 0.2 part of L-tyrosine, 0.06 part of riboflavin (VB2), 0.06 part of nicotinic acid, 0.04 part of pyridoxine hydrochloride, 0.06 part of vitamin C, 0.06 part of vitamin E, 0.15 part of zinc-containing yeast with the zinc content of 10%, 0.15 part of manganese-containing yeast with the manganese content of 5% by mass and 0.15 part of selenium-containing yeast with the selenium content of 0.2% by mass.
In another preferred embodiment of the invention, the antioxidant composition is prepared from the following raw materials in parts by mass: the nutrient solution comprises, by active ingredient, 12 parts of NMN, 100.048 parts of coenzyme Q, 0.24 part of plasmalogen, 0.96 part of DNA, 0.96 part of RNA, 0.08 part of L-tryptophan, 0.06 part of L-tyrosine, 0.04 part of riboflavin (VB2), 0.06 part of nicotinic acid, 0.04 part of pyridoxine hydrochloride (VB6), 0.06 part of vitamin C (L-ascorbic acid P), 0.06 part of vitamin E, 0.06 part of zinc-containing yeast with 10% of zinc content by mass, 0.06 part of manganese-containing yeast with 5% of manganese content by mass and 0.06 part of selenium-containing yeast with 0.2% of selenium content by mass.
In another preferred embodiment of the invention, the antioxidant composition is prepared from the following raw materials in parts by mass: the nutrient solution comprises, by active ingredient, 12.8 parts of NMN, 100.028 parts of coenzyme Q, 0.26 part of plasmalogen, 0.46 part of DNA, 0.46 part of RNA, 0.04 part of L-tryptophan, 0.04 part of L-tyrosine, 0.06 part of riboflavin (VB2), 0.08 part of nicotinic acid, 0.04 part of pyridoxine hydrochloride (VB6), 0.06 part of vitamin C (L-ascorbic acid P), 0.06 part of vitamin E, 0.06 part of zinc-containing yeast with 10 mass percent of zinc, 0.06 part of manganese-containing yeast with 5 mass percent of manganese and 0.06 part of selenium-containing yeast with 0.2 mass percent of selenium.
In the present invention, the raw materials of the antioxidant composition may further include an auxiliary material conventional in the art, such as calcium stearate.
The mass parts of the auxiliary materials can be set according to the conventional method in the field, for example, 0.2-0.5 parts by weight of the effective components, and for example, 0.38 parts by weight.
In the present invention, the dosage form of the antioxidant composition is a dosage form conventional in the art, such as a solid agent or an aqueous agent. Wherein, the solid preparation can be capsules, tablets, pills or granules, and the aqua can be oral liquid.
The invention also provides a preparation method of the antioxidant composition, which comprises the following steps: and mixing the raw materials of the antioxidant composition.
In a preferred embodiment of the present invention, the preparation method further comprises the steps of: sieving the raw materials of the antioxidant composition respectively before mixing; for example, 60 mesh screen.
In a preferred embodiment of the present invention, the preparation method comprises the steps of: and respectively sieving the dried raw materials with a 60-mesh sieve, weighing the sieved raw materials according to the proportion, and uniformly mixing.
In the present invention, the preparation method may further include the steps of granulation, drying and size stabilization according to the conventional method in the art.
The preparation method can also comprise the step of preparing the antioxidant composition into a solid agent or a water agent according to the conventional procedures in the field.
On the basis of the common knowledge in the field, the above preferred conditions can be combined randomly to obtain the preferred embodiments of the invention.
The reagents and starting materials used in the present invention are commercially available.
The positive progress effects of the invention are as follows:
1) in the technical scheme provided by the invention, Nicotinamide Mononucleotide (NMN) can play a role in activating energy metabolism of an organism and improving oxidative stress reaction of the organism, and simultaneously, the synergistic effect of coenzyme Q10, plasmalogen, nucleic acid, amino acid, vitamin and trace elements is matched to play a good role in resisting oxidation, delaying senescence and improving metabolism rate; moreover, each component in the composition has stable structure, is not easy to deteriorate and damage after a corresponding product is prepared, is safe and beneficial to human bodies, and has the advantages of good antioxidant and anti-aging effects, no harm to human bodies and stable product quality.
2) The technical scheme provided by the invention adopts specific components and specific proportion, and has the advantages of reasonable formula, proper compatibility, convenient use, good absorption effect, no adverse effect and no toxic or side effect.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The reagents used in the following examples, unless otherwise specified, were purchased from conventional biochemical reagent stores. The NMN is purchased from korea biotechnology (shanghai) ltd. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.
The experiment evaluates the molding condition and the drug protection effect of the mouse by detecting the contents of SOD, MDA and GSH-Px in the liver of the experimental mouse.
The T-SOD kit, the MDA kit and the GSH-Px kit are all purchased from Nanjing Biotechnology company.
Mice belong to mammals and are the most widely used model organisms in the research of human aging-related mechanisms and the research and development of anti-aging drugs. The aging model manufactured by the method is very close to the natural aging of a human body, and the biochemical index and the physiological index change of the body are highly similar to the natural aging after the aging model is successfully manufactured, so the D-galactose aging model is the most classical aging research model and is widely applied to the research of the aging effect of the body.
Reactive Oxygen Species (ROS) are compounds containing ROS functional groups generated by oxidative systems, and are also the most predominant free radicals in the body. During the aging process of the organism, the production amount of ROS is larger than the clearance amount, and the accumulated ROS can damage organs or tissues to accelerate the aging of the organism. Superoxide Dismutase (SOD) is an active substance originated from living body, can eliminate harmful substances generated in the metabolism process of organism, and has special anti-aging effect by supplementing a certain amount of SOD. Glutathione peroxidase (GSH-Px) is an important peroxidase widely existing in the body. The active center of GSH-Px is selenocysteine, and the activity of the GSH-Px can reflect the selenium level of the body. Selenium is a component of the GSH-Px enzyme system, and can catalyze GSH to change into GSSG, so that toxic peroxide is reduced into a non-toxic hydroxyl compound, and the structure and the function of a cell membrane are protected from being damaged by the peroxide. Malonaldehyde (MDA) is one of the most important products for membrane lipid peroxidation, and excessive MDA production can aggravate membrane damage and has cytotoxicity, so MDA is an important index for aging test.
The ROS generation and elimination in an aging body are closely related to the liver, the liver SOD activity can be obviously reduced and the content of lipid peroxide MDA can be increased in the aging process, so that the ROS elimination capability of the liver is reduced, the ROS accumulation can be promoted, the aging of the body is accelerated, the liver is also an important organ for synthesizing antioxidant enzymes such as Glutathione (GSH), and the like, and the enzyme activity of the GSH can be influenced by aging in the same way.
EXAMPLE 1 preparation of composition capsules
(1) Active raw materials: 10.64g of NMN, 0.6g of aqueous coenzyme Q10 solution (10% by mass of coenzyme Q10), 0.45g of plasmalogen, 0.96g of DNA, 0.96g of RNA, 0.28g L-tryptophan, 0.2g L-tyrosine, 0.06g of riboflavin (VB2), 0.06g of nicotinic acid, 0.04g of pyridoxine hydrochloride (VB6), 0.06g of vitamin C (L-ascorbic acid P), 0.06g of dry vitamin E, 0.15g of yeast containing zinc (10% by mass of zinc), 0.15g of yeast containing manganese (5% by mass of manganese), 0.15g of yeast containing selenium (0.2% by mass of selenium).
(2) Auxiliary materials: 0.38g of calcium stearate
(3) The preparation method comprises the following steps:
and respectively sieving the dried raw materials and the auxiliary materials with a 60-mesh sieve, then proportioning and weighing the screened raw materials, simultaneously adding the related auxiliary materials, and uniformly mixing. The capsule preparation is obtained by filling capsules by a conventional method after the procedures of granulation, drying, granule finishing and the like.
The theoretical mass of the content of each capsule is 260mg, and the theoretical content of NMN is 182 mg.
EXAMPLE 2 preparation of composition capsules
(1) Active raw materials: 12g of NMN, 0.48g of aqueous coenzyme Q10 solution (10% by mass of coenzyme Q10), 0.24g of plasmalogen, 0.96g of DNA, 0.96g of RNA, 0.08g of L-tryptophan, 0.06g of 0.06g L-tyrosine, 0.04g of riboflavin (VB2), 0.06g of nicotinic acid, 0.04g of pyridoxine hydrochloride (VB6), 0.06g of vitamin C (L-ascorbic acid P), 0.06g of dry vitamin E, 0.06g of zinc-containing yeast (10% by mass of zinc), 0.06g of manganese-containing yeast (5% by mass of manganese), 0.06g of selenium-containing yeast (0.2% by mass of selenium).
(2) Auxiliary materials: 0.38g of calcium stearate
(3) The preparation method comprises the following steps:
and respectively sieving the dried raw materials and the auxiliary materials with a 60-mesh sieve, then proportioning and weighing the screened raw materials, simultaneously adding the related auxiliary materials, and uniformly mixing. The capsule preparation is obtained by filling capsules by a conventional method after the procedures of granulation, drying, granule finishing and the like.
The theoretical mass of the content of each capsule is 260mg, and the theoretical content of NMN is 200 mg.
EXAMPLE 3 preparation of composition capsules
(1) Active raw materials: 12.8g of NMN, 0.28g of aqueous coenzyme Q10 solution (10% by mass of coenzyme Q10), 0.26g of plasmalogen, 0.46g of DNA, 0.46g of RNA, 0.04g of L-tryptophan, 0.04g L-tyrosine, 0.06g of riboflavin (VB2), 0.08g of nicotinic acid, 0.04g of pyridoxine hydrochloride (VB6), 0.06g of vitamin C (L-ascorbic acid P), 0.06g of dry vitamin E, 0.06g of yeast containing zinc (10% by mass of zinc), 0.06g of yeast containing manganese (5% by mass of manganese), 0.06g of yeast containing selenium (0.2% by mass of selenium).
(2) Auxiliary materials: 0.38g of calcium stearate
(3) The preparation method comprises the following steps:
and respectively sieving the dried raw materials and the auxiliary materials with a 60-mesh sieve, then proportioning and weighing the screened raw materials, simultaneously adding the related auxiliary materials, and uniformly mixing. The capsule preparation is obtained by filling capsules by a conventional method after the procedures of granulation, drying, granule finishing and the like.
The theoretical mass of the content of each capsule is 260mg, and the theoretical content of NMN is 219 mg.
Comparative example 1NMN + adjuvant composition
The difference from example 3 is that the composition, which is composed of 15.22g NMN and 0.38g calcium stearate, is different in composition, and the preparation method is the same as example 3.
The theoretical mass of the content of each capsule is 260mg, and the theoretical content of NMN is 230 mg.
Test example 1 stability test of composition
The capsule formulations obtained in examples 1 to 3 were stored under long-term storage conditions (30 ℃. + -. 2 ℃ C., RH 65%. + -. 5%) for 12 months in stability test experiments. Testing the content of NMN in the preparation after 0 month, 1 month, 2 months, 3 months, 6 months and 12 months respectively by chromatography, wherein the chromatographic conditions are as follows: a chromatographic column: welch Ultimate AQ-C18(5 μm, 4.6 × 250 mm); buffer solution: 0.05mol/L diammonium hydrogen phosphate: 10% tetrabutylammonium hydroxide aqueous solution 91: 1, adjusting the pH value to 3.6 by phosphoric acid; mobile phase: acetonitrile: buffer 8: 92; flow rate: 1.0 mL/min; detection wavelength: 254 nm; column temperature: 30 ℃; sample introduction amount: 10 mu l of the mixture; operating time: 40 min; diluting liquid: ultrapure water.
The test results are shown in table 1 below:
table 1 stability test results of the compositions
From the test results, the preparation stability of the antioxidant composition containing NMN prepared in the embodiments 1 to 3 is good, the content of NMN is not reduced basically in 0 to 3 months, and the content of NMN is still kept high after 12 months, which shows that the preparation method and the synergistic interaction among the raw material components in the embodiments of the invention are beneficial to improving the stability of NMN and the raw material components in the antioxidant composition containing NMN.
Test example 2 measurement of antiaging Effect of composition
The disclosed antioxidant, anti-aging composition formulations were tested in mice to test their efficacy and safety.
80 adult mice were selected, all mice were acclimatized in the animal room for 2 weeks, and the light was adjusted according to the day rhythm of 12 hours. During the breeding period, the mice can freely enter water and eat food, the temperature of the breeding environment is always kept between 20 and 22 ℃, and the relative humidity is 50 to 60 percent.
After an adaptation period of 2 weeks, the mice were divided into 20 mice per group, which were evenly divided by body weight into a normal group, a model group (D-gal 100 mg/kg/day, representing the administration dose), a control group (using NMN + adjuvant composition 50 mg/kg/day, representing the administration dose in comparative example 1), experimental groups 1, 2 and 3 (using product compositions 50 mg/kg/day, representing the administration dose prepared in examples 1, 2 and 3, respectively), and a control group.
Establishing a model: except for the normal group, the other groups were intraperitoneally injected with D-gal at a dose of 100mg/kg bw daily, and the normal group was intraperitoneally injected with normal saline at the same dose for 10 weeks to establish a subacute aging model.
Starting from the 7 th week, the control group and the experimental group are respectively administered with the corresponding test drug NMN + adjuvant composition and product composition in a gavage mode, and the administration dosage is as above; normal group, model group 100mg/kg bw gastric saline, continued for 4 weeks, after 10 weeks experiment end, fasting without water to kill all experimental mice.
The method comprises the following steps of collecting liver tissues after killing mice, accurately weighing 0.1g of liver tissues in a 2mLEp tube, adding 0.9mL of precooled physiological saline, homogenizing, centrifuging, collecting supernate and subpackaging for later use to prepare homogenate with the mass percentage content of 10%. The protein concentration of the homogenate is firstly measured, and then the contents of T-SOD, MDA and GSH-Px are strictly measured according to the operation of the corresponding kit instruction.
The results of the experiment are shown in table 2 below:
TABLE 2
Note: compared to the normal group:#indicates that the difference is significant (0.01)<P<0.05),##Indicating that the difference is extremely significant (P)<0.01); compared to the model set: indicates significant difference (0.01)<P<0.05) indicates that the difference is extremely significant (P)<0.01)。
From the experimental data it can be seen that: comparing the control group mice treated by the NMN + auxiliary material with the model group, the beneficial factor T-SOD content in the liver tissues of the control group mice treated by the product composition of the embodiments 1, 2 and 3 exceeds the model group and is close to the normal group level, comparing the experimental group mice treated by the product composition of the embodiments 1, 2 and 3 with the model group, the T-SOD content is far beyond the model group and exceeds the normal group and the control group, comparing the control group mice treated by the NMN + auxiliary material composition with the model group, the GSH-Px content in the liver tissues of the control group mice is slightly higher than the model group, comparing the experimental group mice treated by the product composition of the embodiments 1, 2 and 3 with the model group, the GSH-Px content exceeds the model group and is basically close to the normal group level; and thirdly, compared with the model group, the MDA factor content of the control group mice treated by the NMN + auxiliary materials is reduced, compared with the model group, the MDA factor content of the liver tissues of the experimental group mice treated by the product compositions of the embodiments 1, 2 and 3 is lower than that of the model group and is close to the normal group level.
In conclusion, experimental results show that the product composition and the NMN + adjuvant composition of the comparative example 1 can generate an antioxidant effect on the liver of a senescent mouse, can protect the liver of the senescent mouse and can generate a protective effect on the senescent mouse, and the antioxidant effect of the product composition is better than that of the NMN + adjuvant composition of the comparative example 1 through the synergistic effect of the components.
While specific embodiments of the invention have been described above, it will be appreciated by those skilled in the art that this is by way of example only, and that the scope of the invention is defined by the appended claims. Various changes and modifications to these embodiments may be made by those skilled in the art without departing from the spirit and scope of the invention, and these changes and modifications are within the scope of the invention.
Claims (10)
1. The NMN-containing antioxidant composition is characterized by being prepared from the following raw materials in parts by mass based on effective components: 10-13 parts of nicotinamide mononucleotide, 100.02-0.06 parts of coenzyme Q, 0.2-0.5 part of plasmalogen, 0.8-2.0 parts of nucleic acid, 0.05-1 part of amino acid, 0.2-0.5 part of vitamin and 0.005-0.08 part of trace element.
2. The NMN-containing antioxidant composition as claimed in claim 1, wherein the nicotinamide mononucleotide is present in an amount of 10-12.8 parts by mass;
and/or the coenzyme Q10 accounts for 0.028-0.06 parts by mass based on the effective components;
and/or, the mass fraction of the plasmalogen is 0.24-0.45 part based on the effective components;
and/or, the nucleic acid comprises: RNA and/or DNA;
and/or the mass part of the nucleic acid is 0.92-1.92 parts by weight based on the effective components;
and/or, the amino acids include: l-tryptophan and/or L-tyrosine;
and/or the amino acid accounts for 0.08-0.48 part by mass of the effective components;
and/or, the vitamins include: a mixture of one or more of riboflavin, niacin, pyridoxine hydrochloride, vitamin E, and vitamin C;
and/or, the mass part of the vitamin is 0.25-0.3 part by weight based on the effective component;
and/or, the trace elements comprise: a mixture of one or more of zinc, manganese and selenium; the zinc source is preferably zinc-containing yeast, and the mass percentage content of zinc in the zinc-containing yeast is preferably 10%; the source of the manganese is preferably manganese-containing yeast, and the content of manganese in the manganese-containing yeast is preferably 5% by mass; the selenium source is preferably selenium-containing yeast, and the content of selenium in the selenium-containing yeast is preferably 0.2% by mass;
and/or the mass part of the trace elements is 0.005-0.06 part by weight based on the effective components;
and/or the raw materials of the antioxidant composition also comprise auxiliary materials.
3. The NMN containing antioxidant composition of claim 1, wherein the nicotinamide mononucleotide is present in 10.64, 12 or 12.8 parts by mass;
and/or, the coenzyme Q10 accounts for 0.06 part, 0.048 part or 0.026 part by mass based on the effective components;
and/or, the mass portion of the plasmalogen is 0.45 portion, 0.24 portion or 0.26 portion calculated by the effective component;
and/or the mass part of the nucleic acid is 0.92 part or 1.92 part based on the effective components;
and/or, the amino acid is 0.08, 0.14 or 0.48 part by mass based on the effective component;
and/or, the vitamin is 0.26 part, 0.28 part or 0.3 part by mass based on the effective component;
and/or, the mass part of the trace elements is 0.00642 part or 0.0525 part based on the effective components;
and/or, when the raw materials of the antioxidant composition further comprise an auxiliary material, the auxiliary material is 0.2-0.5 part by mass, for example, the auxiliary material is 0.38 part by mass;
and/or when the raw materials of the antioxidant composition further comprise an auxiliary material, the auxiliary material is calcium stearate.
4. The NMN containing antioxidant composition as in claim 1, wherein the antioxidant composition is prepared from raw materials comprising in parts by mass: 10-12.8 parts of nicotinamide mononucleotide, 0.06 part of coenzyme Q100.028, 0.24-0.45 part of plasmalogen, 0.92-1.92 parts of nucleic acid, 0.08-0.48 part of amino acid, 0.25-0.3 part of vitamin and 0.005-0.06 part of trace element.
5. The NMN-containing antioxidant composition as in claim 1, wherein the antioxidant composition is prepared from the following raw materials in parts by mass: 10-12.8 parts of nicotinamide mononucleotide, 0.06 part of coenzyme Q100.028, 0.24-0.45 part of plasmalogen, 0.92-1.92 parts of nucleic acid, 0.08-0.48 part of amino acid, 0.25-0.3 part of vitamin and 0.005-0.06 part of trace element.
6. The NMN containing antioxidant composition as in claim 1, wherein the antioxidant composition is prepared from the following raw materials in parts by mass: 10.64 parts of NMN, 100.06 parts of coenzyme Q, 0.45 part of plasmalogen, 0.96 part of DNA, 0.96 part of RNA, 0.28 part of L-tryptophan, 0.2 part of L-tyrosine, 0.06 part of riboflavin, 0.06 part of nicotinic acid, 0.04 part of pyridoxine hydrochloride, 0.06 part of vitamin C, 0.06 part of vitamin E, 0.15 part of zinc-containing yeast with 10 mass percent of zinc, 0.15 part of manganese-containing yeast with 5 mass percent of manganese and 0.15 part of selenium-containing yeast with 0.2 mass percent of selenium;
or the antioxidant composition is prepared from the following raw materials in parts by mass: 12 parts of NMN, 100.048 parts of coenzyme Q, 0.24 part of plasmalogen, 0.96 part of DNA, 0.96 part of RNA, 0.08 part of L-tryptophan, 0.06 part of L-tyrosine, 0.04 part of riboflavin, 0.06 part of nicotinic acid, 0.04 part of pyridoxine hydrochloride, 0.06 part of vitamin C, 0.06 part of vitamin E, 0.06 part of zinc-containing yeast with 10 mass percent of zinc, 0.06 part of manganese-containing yeast with 5 mass percent of manganese and 0.06 part of selenium-containing yeast with 0.2 mass percent of selenium;
or the antioxidant composition is prepared from the following raw materials in parts by mass: 12.8 parts of NMN, 100.028 parts of coenzyme Q, 0.26 part of plasmalogen, 0.46 part of DNA, 0.46 part of RNA, 0.04 part of L-tryptophan, 0.04 part of L-tyrosine, 0.06 part of riboflavin, 0.08 part of nicotinic acid, 0.04 part of pyridoxine hydrochloride, 0.06 part of vitamin C, 0.06 part of vitamin E, 0.06 part of zinc-containing yeast with 10 mass percent of zinc, 0.06 part of manganese-containing yeast with 5 mass percent of manganese and 0.06 part of selenium-containing yeast with 0.2 mass percent of selenium.
7. The NMN containing antioxidant composition of claim 1, in the form of a solid or aqueous formulation; wherein, the solid agent is preferably capsule, tablet, pill or granule; the aqueous agent is preferably an oral liquid.
8. A process for the preparation of an antioxidant composition as claimed in any one of claims 1 to 7, characterized in that it comprises the following steps: and mixing the raw materials of the antioxidant composition.
9. The method of preparing the antioxidant composition of claim 8, further comprising the steps of: sieving the raw materials of the antioxidant composition respectively before mixing; for example, 60 mesh;
and/or, the preparation method also comprises the procedures of granulation, drying and granule finishing;
and/or the preparation method further comprises the step of preparing the antioxidant composition into a solid agent or a water agent.
10. The method of preparing the antioxidant composition of claim 8, comprising the steps of: and respectively sieving the dried raw materials with a 60-mesh sieve, weighing the sieved raw materials according to the proportion, and uniformly mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011037885.4A CN114272273A (en) | 2020-09-28 | 2020-09-28 | NMN-containing antioxidant composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011037885.4A CN114272273A (en) | 2020-09-28 | 2020-09-28 | NMN-containing antioxidant composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114272273A true CN114272273A (en) | 2022-04-05 |
Family
ID=80867852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011037885.4A Pending CN114272273A (en) | 2020-09-28 | 2020-09-28 | NMN-containing antioxidant composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114272273A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115812953A (en) * | 2022-12-22 | 2023-03-21 | 中国农业科学院果树研究所 | Cough relieving soft extract and preparation method thereof |
| CN116114796A (en) * | 2022-10-31 | 2023-05-16 | 山东省海洋资源与环境研究院(山东省海洋环境监测中心、山东省水产品质量检验中心) | Stress protective agent and preparation method and application thereof |
-
2020
- 2020-09-28 CN CN202011037885.4A patent/CN114272273A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116114796A (en) * | 2022-10-31 | 2023-05-16 | 山东省海洋资源与环境研究院(山东省海洋环境监测中心、山东省水产品质量检验中心) | Stress protective agent and preparation method and application thereof |
| CN116114796B (en) * | 2022-10-31 | 2024-04-02 | 山东省海洋资源与环境研究院(山东省海洋环境监测中心、山东省水产品质量检验中心) | A stress protective agent and its preparation method and application |
| CN115812953A (en) * | 2022-12-22 | 2023-03-21 | 中国农业科学院果树研究所 | Cough relieving soft extract and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lai | Chlorophyll: The active factor in wheat sprout extract inhibiting the metabolic activation of carcinogens in vitro | |
| Que et al. | In vitro and vivo antioxidant activities of daylily flowers and the involvement of phenolic compounds | |
| WO2020224027A1 (en) | Composition containing glucoraphanin and use thereof | |
| KR102299934B1 (en) | Composition for preventing or treating liver damage by alcohol which is excellent in hangover resolution | |
| JP2022054483A (en) | Nmn-containing antioxidant composition and method for preparing the same | |
| CN114272273A (en) | NMN-containing antioxidant composition and preparation method thereof | |
| EP2779842B1 (en) | Composition for protection against cell-damaging effects | |
| CN113170889A (en) | Compound anti-aging composition, compound anti-aging tablet, and preparation method and application thereof | |
| KR20160021734A (en) | Antioxidative composition comprising extract of red tea stem | |
| ES2308550T3 (en) | FORMULATION FOR ORAL ADMINISTRATION EXERCISING A RECONSTITUENT EFFECT ON THE CARDIOVASCULAR SYSTEM. | |
| JP4974553B2 (en) | Acetaldehyde metabolism promoter | |
| JP2025503748A (en) | Anti-aging composition containing uridylic acid, adenylic acid and yeast peptides and use thereof | |
| US11571438B1 (en) | Nutraceutical compositions to up-regulate SIRT1 and methods of use | |
| KR20220130003A (en) | Liquid supplementary feed composition containing coenzyme Q10 | |
| CN116801733A (en) | Compositions for targeting advanced glycation end product Receptor (RAGE) in chronic inflammatory disorders | |
| KR20230027971A (en) | Liquid composition of liposome improved in absorption and properties stability of vitamin c | |
| EP2736507B1 (en) | Basic alpha lipoic acid solution and its uses | |
| Esan et al. | The Effects of okra (Abelmoschus esculentus (L) M oench) fruit extracts on diabetes markers in streptozotocin-induced diabetic rats. Arch | |
| EP2452577B1 (en) | Aqueous solution of phytin and use of said solution for preparing a liquid food supplement or a cosmetic composition | |
| RU2436415C2 (en) | Composition of biologically active substances based on betulin with regulated rate of releasing components for reducing degree of alcohol intoxication, preventing and relieving alcohol intoxication and alcohol withdrawal syndrome | |
| KR20200107809A (en) | Vitamin complex formula coated with xylitol and or Enzymatically Modified Stevia | |
| JP2023062717A (en) | Nmn-containing antiaging composition | |
| CN104431998A (en) | An anthocyanin health product for antioxidation | |
| EP2388011B1 (en) | Antioxidant composition for reducing oxidative stress in dogs | |
| EP3231296A1 (en) | Use of a composition comprising alpha-lipoic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220405 |
|
| WD01 | Invention patent application deemed withdrawn after publication |